On 16 July 2025 the Court of Appeal (Peter Jackson, Arnold & Stuart-Smith LJJ) handed down judgment in the expedited appeal Generics (U.K.), Teva & Glenmark v AstraZeneca [2025] EWCA Civ 903.

The judgment can be found here:

https://caselaw.nationalarchives.gov.uk/ewca/civ/2025/903.

The Court upheld the decision at first instance that AstraZeneca’s patent EP 1506211 (and SPCs) covering its diabetes product dapagliflozin (Forxiga) was invalid for lack of plausibility and lack of technical contribution. The decision discusses the question of plausibility and the effect of the EBA decision in G2/21.

Tom Mitcheson KC acted for Generics (U.K.), Teva & Glenmark, Tim Austen acted for Teva. Tom Hinchliffe KC, Stuart Baran, Thomas Lunt and Dheemanth Vangimalla acted for AstraZeneca.